A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer

Clinical trial NCT02443883 · COMPLETED

Trial details

NCT number: NCT02443883
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

Start date: 2015-07-07
Primary completion: 2016-11-18
Enrollment: 164

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.